- Seqster — a leader in patient-centric healthcare data technology — announced recently that it has raised $12M in a Series A round of venture capital financing. These are the details.
Seqster — a leader in patient-centric healthcare data technology — announced recently that it has raised $12M in a Series A round of venture capital financing. And the funding round was led by OmniHealth Holdings LLC with additional investment from Takeda Digital Ventures and 23andMe’s CEO and Founder, Anne Wojcicki.
This investment is fueling Seqster’s ability to grow and evolve its technology to meet the demand for its multi-dimensional healthcare data platform. And Seqster provides patient engagement with proprietary technology to access secure, longitudinal, and comprehensive healthcare data in real-time, both at the patient level and at scale. This includes electronic health records (EHRs), pharmacy data, lab data, genomic data (DNA), fitness wearables data, and social determinants of health (SDOH).
Seqster was founded in 2016 by Ardy Arianpour, Dr. Xiang Li, and Dana Hosseini in order to directly address healthcare’s fundamental problem of data silos and fragmented health data. And automated data collection in real-time is even more critical during the COVID-19 pandemic, especially in the clinical trial setting. Leading bio-pharmaceutical companies have also been using the Seqster platform for remote clinical trials around the world.
KEY QUOTES:
“Seqster was built on the foundation that real-time access to a patient’s complete medical history can solve major pain points across the healthcare continuum, impacting lives at scale. We are excited to have investors who are experienced operators and who share our mission and vision to change the way an enterprise or a patient can capture, refine and manage a multitude of disparate data sources in real-time, and present that aggregate in a way that solves real healthcare challenges.”
— Ardy Arianpour, CEO and co-founder of Seqster
“Seqster is solving one of healthcare’s biggest challenges – siloed data, and they have done so with a solution that is comprehensive, easy to deploy, and scalable. Seqster has provided significant value in the pharmaceutical world by making it easier to recruit and track clinical trial participants. The company is making significant inroads in the healthcare space, where access to complete longitudinal patient data will lower costs and improve patient outcomes. This new investment will enable the company to expand further into healthcare, where Seqster’s software has numerous applications.”
— Tim O’Donnell, Managing Partner of OmniHealth Holdings
